Iqvia Holdings INC.: directors' dealings · United States · SEC (Form 4)

About Iqvia Holdings INC.

IQVIA Holdings Inc. (NYSE: IQV) is a leading global player in life sciences and healthcare services, operating at the intersection of data, technology and clinical research. The company is headquartered in Durham, North Carolina, United States, and maintains a broad global footprint across more than 100 countries with approximately 93,000 employees. IQVIA was created in 2016 through the merger of Quintiles and IMS Health, and the combined company adopted the IQVIA brand in 2017. ([iqvia.com](https://www.iqvia.com/about-us)) IQVIA’s business model is now built around two core operating pillars. On the R&D side, the company provides clinical trial services, patient and site solutions, central laboratory services, functional outsourcing and R&D consulting. On the commercial side, IQVIA offers analytics, market intelligence, commercial engagement services, patient support and decision-support tools for pharma and other healthcare clients. Its IQVIA Connected Intelligence platform and healthcare-grade AI capabilities are central to its value proposition, linking healthcare data, technology and domain expertise. ([iqvia.com](https://www.iqvia.com/about-us)) From a competitive standpoint, IQVIA stands out because it combines one of the industry’s deepest data assets with global clinical execution capabilities and increasingly sophisticated software and analytics offerings. That makes it a strategic partner for large pharmaceutical companies, biotech firms, medtech players, payers and certain public-sector organizations. The company also benefits from broad therapeutic coverage, spanning oncology, rare diseases, cardiovascular care, vaccines, central nervous system disorders and endocrinology. ([iqvia.com](https://www.iqvia.com/about-us)) IQVIA’s international presence is a key advantage in an industry where multinational trials, complex regulation and real-world evidence generation require cross-border scale. The company’s services are used across clinical development, commercialization, safety and healthcare intelligence workflows, giving it a diversified exposure across the biopharma value chain. ([iqvia.com](https://www.iqvia.com/about-us)) Recent developments reinforce that strategic positioning. In May 2026, IQVIA reported strong first-quarter 2026 results, with growth in both major segments, and reaffirmed its full-year 2026 guidance. Earlier in 2026, the company also simplified its internal operating model, announced a strategic commercial data collaboration, and signed an agreement to acquire drug-discovery assets from Charles River Laboratories to expand its end-to-end discovery capabilities. Collectively, these moves point to a business increasingly focused on AI, operating efficiency and extending its reach further upstream and downstream in the pharmaceutical value chain. ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2026/IQVIA-Reports-First-Quarter-2026-Results/default.aspx?utm_source=openai))